renal transplant liver transplant heart transplant cotrimoxazole bactrim Pneumocystis Transplant Recipients
Conditions
Interventions
After transplantation, participants will receive a single dose of trimethoprim/sulfamethoxazole once daily, for at least 6 months if no any further contraindication occured. The participants will the
Experimental Drug,Experimental Drug
single-dose once daily,double-dose thrice weekly
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. solid organ transplant recipient
Exclusion criteria
Exclusion criteria: 1. trimethoprim/sulfamethoxazole allergy 2. underlying Glucose-6-Phosphate Dehydrogenase deficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pneumocystis jirovecii pneumonia 24 months after drug initiation Chest X-ray, CT scan of chest, Sputum for PJP PCR or GMS, Expert opinion from transplant infectious physician or pulmonologist | — |
Secondary
| Measure | Time frame |
|---|---|
| hepatitis after drugs initiation aspartate aminotransferase, alanine aminotransferase, symptoms (e.g., nausea, vomitting) | — |
Countries
Thailand
Contacts
Public ContactWittawin Chantapoh
Faculty of Medicine Ramathibodi Hospital
Outcome results
None listed